Advertisement
Advertisement

NAMS

NAMS logo

NewAmsterdam Pharma Company N.V. Ordinary Shares

32.41
USD
Sponsored
+1.01
+3.22%
Jun 24, 15:43 UTC -4
Open

NAMS Earnings Reports

Positive Surprise Ratio

NAMS beat 6 of 11 last estimates.

55%

Next Report

Date of Next Report
Aug 04, 2026
Estimate for Q2 26 (Revenue/ EPS)
$1.70M
/
-$0.49
Implied change from Q1 26 (Revenue/ EPS)
-44.21%
/
+22.50%
Implied change from Q2 25 (Revenue/ EPS)
-91.14%
/
+226.67%

NewAmsterdam Pharma Company N.V. Ordinary Shares earnings per share and revenue

On May 07, 2026, NAMS reported earnings of -0.40 USD per share (EPS) for Q1 26, beating the estimate of -0.50 USD, resulting in a 20.32% surprise. Revenue reached 3.04 million, compared to an expected 875.50 thousand, with a 247.23% difference. The market reacted with a +12.46% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 10 analysts forecast an EPS of -0.49 USD, with revenue projected to reach 1.70 million USD, implying an increase of 22.50% EPS, and decrease of -44.21% in Revenue from the last quarter.
FAQ
For Q1 2026, NewAmsterdam Pharma Company N.V. Ordinary Shares reported EPS of -$0.40, beating estimates by 20.32%, and revenue of $3.04M, 247.23% above expectations.
The stock price moved up 12.46%, changed from $30.99 before the earnings release to $34.85 the day after.
The next earning report is scheduled for Aug 04, 2026.
Based on 10 analysts, NewAmsterdam Pharma Company N.V. Ordinary Shares is expected to report EPS of -$0.49 and revenue of $1.70M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement